TheraRadar
Clinical-Stage Companies / Genrix (Shanghai) Biopharmaceutical

Genrix (Shanghai) Biopharmaceutical

Pre-Approval PRO BETA
22
Total Trials
7
Phase 3
11
Phase 2
11
Recruiting
268
Score

Pipeline by Phase

Phase 3
7
Phase 2
11
Phase 1
10

Therapeutic Focus

Multiple Myeloma Allergic Rhinitis, Seasonal Tetanus Axial Spondyloarthritis Systemic Lupus Erthematosus

Clinical Trials (22)

NCT07452198 Phase 3 RECRUITING

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Started: 3/9/2026

NCT07154342 Phase 3 RECRUITING

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis

Started: 8/15/2025

NCT06635798 Phase 3 RECRUITING

A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

Started: 9/3/2024

NCT06516302 Phase 3 ACTIVE NOT RECRUITING

A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps

Started: 9/19/2024

NCT07199257 Phase 3 NOT YET RECRUITING

A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis.

Started: 9/25/2025

NCT05846568 Phase 3 COMPLETED

Study to Evaluate GR1801's Efficacy and Safety

Started: 10/21/2022

NCT05881785 Phase 3 COMPLETED

Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis

Started: 6/13/2022

NCT06952075 Phase 2 RECRUITING

GR1803 Injection in Patients With RRMM

Started: 4/24/2025

NCT06566547 Phase 2 ACTIVE NOT RECRUITING

GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma

Started: 8/26/2024

NCT06315426 Phase 2 ACTIVE NOT RECRUITING

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).

Started: 3/24/2024

NCT05873803 Phase 2 ACTIVE NOT RECRUITING

The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

Started: 2/8/2023

NCT05162937 Phase 2 COMPLETED

to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis

Started: 9/7/2020

NCT07348055 Phase 1 RECRUITING

A Study of GR1803 in Systemic Lupus Erythematosus

Started: 2/2/2026

NCT07199270 Phase 1 RECRUITING

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

Started: 9/18/2025

NCT07190716 Phase 1 NOT YET RECRUITING

A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.

Started: 10/10/2025

NCT07102706 Phase 1 COMPLETED

Phase I Trial of GR1803 Injection in Patients With RRMM

Started: 5/27/2022

NCT07090954 Phase 1 NOT YET RECRUITING

A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Started: 8/31/2025

NCT06015230 Phase 1 ACTIVE NOT RECRUITING

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

Started: 3/8/2022

NCT05954611 Phase 1 COMPLETED

The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers

Started: 6/16/2023

NCT06302374 Phase 1 COMPLETED

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

Started: 3/4/2023

NCT07647237 Phase 1 NOT YET RECRUITING

A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo

Started: 6/1/2026

NCT07647224 Phase 1 NOT YET RECRUITING

A Clinical Trial of Multiple Doses of GR2301 Injection in Healthy Adult Trial Participants in China.

Started: 6/1/2026

Drug Candidates

GR1803 injection GR1802 GR1802 injection GR2303 injection GR2301 injection Anti-CD38 Monoclonal Antibody GR1803 GR2001 HTIG GR1801
Activity Status: Active
Last Trial Started: 6/1/2026
Last Trial Ended: 5/20/2025
Trials (12 months): 9
Completed Trials: 6
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.